| Literature DB >> 18039366 |
Jin Zhang1, Qiang He, Qiu Y Liu, Wei Guo, Xue M Deng, Wei W Zhang, Xiao X Hu, Ning Li.
Abstract
BACKGROUND: Clenbuterol, a beta-agonist, can dramatically reduce pig adipose accumulation at high dosages. However, it has been banned in pig production because people who eat pig products treated with clenbuterol can be poisoned by the clenbuterol residues. To understand the molecular mechanism for this fat reduction, cDNA microarray, real-time PCR, two-dimensional electrophoresis and mass spectra were used to study the differential gene expression profiles of pig adipose tissues treated with/without clenbuterol. The objective of this research is to identify novel genes and physiological pathways that potentially facilitate clenbuterol induced reduction of adipose accumulation.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18039366 PMCID: PMC2231380 DOI: 10.1186/1471-2164-8-433
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Body composition of pigs treated with/without clenbuterol
| Age | 3 month-old | 3 month-old | 4 month-old | 4 month-old | ||||
| Clenbuterol dosage* | 0 | 25 | 0 | 50 | ||||
| Pig | Hog 2 | Sow 2 | Hog 1 | Sow 1 | Hog 4 | Sow 4 | Hog 3 | Sow 3 |
| Lean meat percentage of carcass (%) | 52.34 | 52.46 | 55.09 | 55.39 | 41.38 | 41.52 | 52.36 | 52.52 |
| Thickness of back fat (cm) | 2.361 | 2.311 | 2.132 | 2.104 | 3.229 | 3.171 | 2.824 | 2.812 |
| Loin muscle area (cm2) | 19.460 | 19.516 | 24.086 | 24.312 | 23.063 | 23.103 | 25.228 | 25.312 |
*twice daily with the unit of (mg/kg body weight)
The carcass lean meat percentage, the back fat thickness and the loin muscle area were all changed statistically in both the 3 month-old group and the 4 month-old group after clenbuterol treatment (P < .05).
Figure 11A. Skeleton muscle (biceps femoris) histological section of pigs with/without the administration of clenbuterol. 1. transverse, test pigs. 2. transverse, control pigs. 3. longitudinal, test pigs. 4. longitudinal, control pigs. Vertical fiber sections analyzed with TD2000 real-color pathology image analysis system (Beijing Tiandibainian Scientific Company Ltd.). The muscle fibers of pigs become thicker when treated with clenbuterol. 1B. Subcutaneous back fat (at the fifth lumbar vertebra level) histological section of pigs with/without the administration of clenbuterol. 1. amplified10 × 10 of test pigs. 2. amplified 10 × 10 of control pigs. 3. amplified 10 × 40 of test pigs. 4. amplified 10 × 40 of control pigs. The sizes of the pig adipose cells decreased when treated with clenbuterol. The cell size was analyzed by counting cells on the slide visible through the microscope eyepiece.
Figure 282 genes were differentially expressed in the DNA microarray analysis in pig fat tissue with clenbuterol administration (P < .05) in both groups. A. The black circle indicates the 507 differentially expressed genes in the 3 month-old group (P < .05 in four microarray slides). B. The cross-hatched circle indicates the 336 differentially expressed genes in the 4 month-old group (P < .05 in four microarray slides). C. The overlapping region indicates the 82 differentially expressed genes in both the 3 month old group and the 4 month old group that were of interest.
Group I of differentially expressed genes: Cell metabolism
| Apolipprotein D (ApoD) | Lipid metabolism | 1.76 | 1.67 | |
| Apolipprotein R (ApoR) | Lipid metabolism | 2.58 | 1.80 | |
| Canis familiaris similar to phosphatidic acid phosphatase type 2A isoform 1, transcript variant 2 | Lipid metabolism | 1.27 | 1.14 | |
| transforming growth factor beta-stimulated protein | modulates the frequency, rate or extent of DNA-dependent transcription | 1.25 | 1.13 | |
| NRAS-related gene (D1S155E) | 1.25 | 1.54 | ||
| KIAA0737 gene product (KIAA0737) | 1.28 | 1.43 | ||
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1) | 1.23 | 1.64 | ||
| ribosomal protein L17 (RPL17), mRNA | protein translation | 1.47 | 1.09 | |
| ribosomal protein S10 | protein translation | 1.33 | 1.15 | |
| cathepsin B | lysosomal cysteine proteinase | 1.14 | 1.13 | |
| Eukaryotic translation elongation factor 1 alpha (EEF1A) | protein translation | 1.70 | 1.29 | |
| archain 1 | endoplasmic reticulum to Golgi transport | 2.15 | 1.62 | |
| L-3-hydroxyacyl-CoA dehydrogenase precursor (HAD) mRNA, | Lipid metabolism | -1.30 | 1.11 | |
| Sus scrofa stearoyl-CoA desaturase (SCD) gene, exons 1 through 6 and complete cds | Lipid metabolism | -1.89 | 1.03 | |
| ribosomal protein L10a | protein translation | -1.01 | 1.03 | |
| ribosomal protein L32 | Protein translation | -1.79 | -1.01 | |
*according to description of the Gene Ontology Biological Process Category
*All the genes in the table were differentially expressed according to the student t test in the eight microarray slides (P < .05)
Group II of differentially expressed genes: Signal transduction*
| cAMP dependent protein kinase type I regulatory (PRKAR1A) | causes the dissociation of the inactive holoenzyme | 2.0 | 2.0 | |
| mRNA encoding G-beta like protein (RACK1) | a physiological mediator of agonist-induced Ca2+ release | 1.29 | 1.05 | |
| wingless-type MMTV integration site family, member 3A (WNT3A) | leads to an increase in intracellular calcium and activation of protein kinase C (PKC) | 1.27 | 1.09 | |
| RAB30 | member of the RAS oncogene family | 2.05 | 2.41 | |
| fibromodulin | participate in the assembly of the extracellular matrix as it interacts with type I and type II collagen fibrils | 1.28 | 1.04 | |
| S100 calcium binding protein A6 | helps stimulation Ca2+-dependent insulin release, prolactin secretion and exocytosis | 5.96 | 1.61 | |
| transmembrane 4 superfamily protein (SAS) | growth-related cellular processes | 1.09 | 1.21 | |
| voltage-dependent anion channel 3 (VDAC3) | Calcium signaling pathway | -1.26 | -1.05 | |
| thrombospondin 4 (THBS4) | forms a pentamer and can bind to heparin and calcium | -1.04 | 1.11 | |
| Homo sapiens CXXC finger 5, mRNA | up-regulation of I-kappaB kinase/NF-kappaB cascade | -1.41 | 1.04 | |
*according to description of the Gene Ontology Biological Process Category
*All the genes in the table were differentially expressed according to the student t test in the eight microarray slides (P < .05)
Group III of differentially expressed genes: Expressed Sequence Tags (ESTs)
| rpfat_9071 | 1.05 | 1.06 | |
| rpig_3811 | 1.63 | 1.42 | |
| rpfat_19982 | 1.41 | 1.27 | |
| rpig_3786 | 1.01 | 1.10 | |
| rpfat_11284 | 1.21 | 1.21 | |
| rpfat_17910 | 1.55 | 1.05 | |
| rpfat_15361 | 1.58 | 1.25 | |
| rpfat_15914 | 1.38 | 1.13 | |
| rpfat_16368 | 1.55 | 1.12 | |
| rpfat_18461 | 1.33 | 1.07 | |
| rpfat_11050 | 1.41 | 1.17 | |
| rpigfat_10350 | 1.84 | 1.21 | |
| rpigfat_10251 | 1.36 | 1.21 | |
| rpig_3845 | 1.06 | 1.09 | |
| rpfat_9552 | 1.05 | 1.08 | |
| rpfat_19923 | 1.24 | 1.08 | |
| rpfat_16045 | 1.36 | 1.18 | |
| rpigfat_10253 | 1.77 | 1.26 | |
| rpig_4030 | 1.07 | 1.11 | |
| rpfat_13525 | 1.49 | 1.14 | |
| rpfat_5467 | 1.79 | 1.58 | |
| rpfat_18469 | 1.18 | 1.14 | |
| rpfat_9125 | 1.34 | 1.24 | |
| rpfat_8471 | 2.32 | 1.37 | |
| rpfat_17820 | 1.39 | 1.13 | |
| rpfat_16623 | 1.54 | 1.22 | |
| rpfat_17845 | 1.21 | 1.38 | |
| rpigfat_10285 | 1.40 | 1.08 | |
| rpfat_18411 | 1.97 | 1.57 | |
| rpfat_12523 | 1.52 | 1.33 | |
| rpig_3750 | 1.60 | 1.43 | |
| rpfat_17081 | 1.57 | 1.14 | |
| rpfat_10949 | 1.08 | 1.16 | |
| rpfat_11494 | 1.05 | 1.21 | |
| rpfat_11443 | 1.09 | 1.46 | |
| rpfat_18636 | 1.83 | 1.22 | |
| rpigfat_9891 | -1.28 | 1.04 | |
| rpfat_19175 | -2 | 1.00 | |
| rpfat_18872 | -1.28 | 1.03 | |
| rpfat_10950 | -1.59 | 1.02 | |
| rpig_3746 | -1.03 | 1.10 | |
| rpfat_11274 | -1.35 | 1.01 | |
| rpfat_12459 | -1.10 | 1.08 | |
| rpfat_15623 | -1.51 | 1.13 | |
| rpfat_11483 | -1.42 | -1.06 | |
*All the genes in the table were differentially expressed according to the student t test in the eight microarray slides (P < .05)
Group IV of differentially expressed genes: Various categories*
| transmembrane protein BRI | developmental processes | 1.27 | 1.13 | |
| D-prohibitin mRNA | developmental processes | 1.54 | 1.24 | |
| collagen, type I, alpha 2 (COL1A2) | developmental processes | 2.48 | 1.53 | |
| mRNA encoding Pro-alpha-2 chain of type I procollagen (COL1A2) | cell structure and mobility | 4.20 | 2.52 | |
| mRNA for KIAA1181 protein | cellular localization | 1.29 | 1.08 | |
| mRNA 3' region for pro-alpha1(III) collagen(COL3A1) | cell structure and mobility | 3.16 | 4 | |
| mRNA for prepro-alpha1(I) collagen (COL1A1) | cell structure and mobility | 2.86 | 2.86 | |
| mRNA for pro-alpha-1 type 3 collagen (COL3A1) | cell structure and mobility | 3.29 | 3.33 | |
| Homo sapiens peptidylprolyl isomerase A (cyclophilin A) | protein folding and stabilization | 1.28 | 1.05 | |
| capping protein (actin filament) muscle Z-line, alpha | cell mobility | 2.02 | 1.61 | |
| minichromosome maintenance deficient (mis5, S. pombe) 6 | cell cycle | 1.75 | 1.62 | |
*according to description of the Gene Ontology Biological Process Category
*All the genes in the table were differentially expressed according to the student t test in the eight microarray slides (P < .05).
Real-time PCR validation of microarray positive results
| Gene* | Hog 3/hog 4 | Sow 3/sow 4 | ||
| Change (test/control) | P value | Change (test/control) | P value | |
| ApoD (rpfat_18926) | 12.28 | 0.013 | 7.49 | 0.002 |
| PRKAR1A(rpfat_17661) | 6.65 | 0.014 | 8.18 | 0.046 |
| COL1A1 (rpfat_8523) | 20.08 | 0.00008 | 13.47 | 0.00001 |
| COL1A2 (rpfat_16033) | 2.87 | 0.0010 | 3.66 | 0.0078 |
| COL1A2 (rpfat_17393) | 3.00 | 0.0002 | 2.29 | 0.0002 |
| COL3A1(rpfat_18309) | Not detected | Not detected | Not detected | Not detected |
| COL3A1 (rpfat_19990) | Not detected | Not detected | Not detected | Not detected |
* The full names of each gene are listed in Tables 2-5.
Five of the seven genes were confirmed by real-time PCR.
Real-time PCR validation of microarray negative results
| Gene* | Hog 1/hog 2 | Sow 1/sow 2 | Hog 3/hog 4 | Sow 3/sow 4 | ||||
| Change (test/control) | P value | Change (test/control) | P value | Change (test/control) | P value | Change (test/control) | P value | |
| SCD (rpfat_16685) | 1.56 | 0.1680 | 0.77 | 0.2119 | 1.49 | 0.0822 | 1.23 | 0.9943 |
| HSL (rpfat_11096) | 1.29 | 0.0679 | 1.11 | 0.2989 | 1.29 | 0.3462 | 1.06 | 0.5294 |
| PMP22a (rpfat_18575) | 1.15 | 0.6198 | 1.16 | 0.3178 | 1.24 | 0.6900 | 1.46 | 0.1175 |
| PHPT1b (rpfat_15312) | 0.75 | 0.1218 | 0.95 | 0.5811 | 1.24 | 0.4694 | 1.46 | 0.4869 |
* The full names of each gene are listed in Tables 2-5.
a : PMP22: peripheral myelin protein 22
b :PHPT1: Phosphohistidine phosphatase 1
Three genes (HSL, PMP22 and PHPT1) were confirmed by real-time PCR.
Figure 3Proteomic study of adipose tissue of pigs with/without the administration of clenbuterol. A. Two-dimensional gel analysis of total proteins from adipose tissue treated with/without clenbuterol. (13% SDS-PAGE, silver stain) 600 ± 50 protein spots were detected. B. Two differentially expressed protein spots (Amplified from the frame in A).
Primers used for the real-time PCR analysis
| Genes & clone number | Primer sequence (5' to 3') | PCR product size (bp) | Annealing Temperature |
| GAPDH | For. ATGGTGAAGGTCGGAGTGA Rev. ATGGGTAGAATCATACTGGA | 154 bp | 57°C |
| Beta 2-microglobulin (B2M) | For. TGG TCTTTCTACCTTCTGGCCC Rev. TGTGATGCCGGTTAGTGGTCTC | 166 bp | 60°C |
| Apolipoprotein D (rpfat_18926) | For. AGATCCCAGTGAGCTTTGAG Rev. CGTAGTTCTCATAGTCGGTG | 233 bp | 58°C |
| PRKAR1A (rpfat_17661) | For. GGCGACGAGGTGCTATCAG Rev. ATGGCATCAAAAATATCAC | 159 bp | 60°C |
| COL1A1 (rpfat_8523) | For. TCAAGATGTGCCACTCCGACT Rev. GCCTGTCTCCATGTTGCAGAA | 104 bp | 60°C |
| COL1A2 (rpfat_16033) | For. ATATGCACCTTGGACATCGGT Rev. CACGATGCTCTGATCAATCCT | 241 bp | 60°C |
| COL3A1 (rpfat_19990) | For. CCTGCTGGAAAGAATGGTGAC Rev. ACGTTCACCGGTTTCACCTT | 132 bp | 60°C |
| COL1A2 (rpfat_17393) | For. CCTGGCTCTAGAGGTGAACG Rev. AGCAGGACCAGGATTACCAG | 247 bp | 60°C |
| COL3A1 (rpfat_18309) | For. TTTCTTTTATGGCTCCCCCTG Rev. GCGTGTTCGATATTCGAAGAC | 101 bp | 60°C |
| SCD (rpfat_16685) | For. AAGGAACTAGAAGGCTGCTC Rev. TGTAGAGCAGCAGCCATCAC | 156 bp | 58°C |
| PHPT1 (rpfat_15312) | For. GAAGACACAGTTGAGGACAC Rev. GGACATTGTTCGGAGGATAG | 110 bp | 60°C |
| HSL (rpfat_11096) | For. TCCGAATGGAGTCTGCACTGT Rev. CTTCCACTCTGACCTCCAACG | 128 bp | 60°C |
| PMP22 (rpfat_18575) | For. CATGAACATTTGCACCACTTG Rev. GTCAGCACCTAATGGTATGGA | 133 bp | 60°C |
For.: Forward
Rev.: Reverse